SG11201406547YA - Nuclease-mediated targeting with large targeting vectors - Google Patents
Nuclease-mediated targeting with large targeting vectorsInfo
- Publication number
- SG11201406547YA SG11201406547YA SG11201406547YA SG11201406547YA SG11201406547YA SG 11201406547Y A SG11201406547Y A SG 11201406547YA SG 11201406547Y A SG11201406547Y A SG 11201406547YA SG 11201406547Y A SG11201406547Y A SG 11201406547YA SG 11201406547Y A SG11201406547Y A SG 11201406547YA
- Authority
- SG
- Singapore
- Prior art keywords
- targeting
- nuclease
- mediated
- vectors
- targeting vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 | |
| PCT/US2013/038165 WO2013163394A1 (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406547YA true SG11201406547YA (en) | 2014-11-27 |
Family
ID=48289700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702445TA SG10201702445TA (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
| SG11201406547YA SG11201406547YA (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702445TA SG10201702445TA (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (en) |
| EP (1) | EP2847335B1 (en) |
| JP (1) | JP6275120B2 (en) |
| KR (1) | KR101904508B1 (en) |
| CN (2) | CN109536526B (en) |
| AU (1) | AU2013251558B2 (en) |
| CA (1) | CA2869016C (en) |
| CY (1) | CY1120572T1 (en) |
| DK (1) | DK2847335T3 (en) |
| ES (1) | ES2683071T3 (en) |
| HK (1) | HK1207396A1 (en) |
| IL (1) | IL234905B (en) |
| IN (1) | IN2014DN09261A (en) |
| MX (1) | MX362523B (en) |
| PL (1) | PL2847335T3 (en) |
| PT (1) | PT2847335T (en) |
| RU (1) | RU2645475C2 (en) |
| SG (2) | SG10201702445TA (en) |
| WO (1) | WO2013163394A1 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201702445TA (en) | 2012-04-25 | 2017-04-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| RS64622B1 (en) | 2012-05-25 | 2023-10-31 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| KR102006880B1 (en) | 2012-12-06 | 2019-08-02 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
| ES2904803T3 (en) | 2013-02-20 | 2022-04-06 | Regeneron Pharma | Genetic modification of rats |
| RS58255B1 (en) | 2013-04-16 | 2019-03-29 | Regeneron Pharma | Targeted modification of rat genome |
| EP3418379B1 (en) * | 2013-09-18 | 2020-12-09 | Kymab Limited | Methods, cells & organisms |
| KR101566498B1 (en) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | Interleukin 2 receptor gamma gene targeting vector, production of SCID-like miniature pigs by TALEN-mediated gene targeting and use thereof |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| WO2015088643A1 (en) * | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| RU2704283C9 (en) * | 2014-06-06 | 2020-02-07 | Регенерон Фармасьютикалз, Инк. | Methods and compositions for modifying target locus |
| ES2694629T3 (en) * | 2014-06-26 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for objective genetic modifications and methods of use |
| ES2741387T3 (en) | 2014-10-15 | 2020-02-10 | Regeneron Pharma | Methods and compositions for generating or maintaining pluripotent cells |
| PT3221457T (en) | 2014-11-21 | 2019-06-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
| KR102530821B1 (en) * | 2014-12-19 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| ES2955841T3 (en) | 2015-03-16 | 2023-12-07 | Regeneron Pharma | Cell from a rodent that has decreased upper and lower motor neuron function and sensory perception |
| KR102377189B1 (en) | 2015-05-29 | 2022-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | C9orf72 - non-human animals having a disruption in a c9orf72 locus |
| AU2017336100B2 (en) | 2016-09-30 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
| US11696572B2 (en) | 2017-06-27 | 2023-07-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ASGR1 locus |
| CA3067872A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
| CN110891419A (en) | 2017-07-31 | 2020-03-17 | 瑞泽恩制药公司 | Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids |
| CA3068072A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
| MX2020003589A (en) | 2017-09-29 | 2020-07-22 | Regeneron Pharma | Non-human animals comprising a humanized. |
| EP3585163B1 (en) | 2017-11-10 | 2022-03-09 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising slc30a8 mutation and methods of use |
| AU2018375796A1 (en) | 2017-11-30 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
| KR20240038811A (en) | 2018-03-19 | 2024-03-25 | 리제너론 파마슈티칼스 인코포레이티드 | Transcription modulation in animals using crispr/cas systems |
| KR102545031B1 (en) | 2018-09-13 | 2023-06-20 | 리제너론 파마슈티칼스 인코포레이티드 | Complement factor H gene knockout rats as a C3 glomerulopathy model |
| JP7449291B2 (en) | 2018-12-20 | 2024-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Nuclease-mediated repeat expansion |
| US11737435B2 (en) | 2019-04-04 | 2023-08-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| MX2021015122A (en) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus. |
| RU2722933C1 (en) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Dna protease cutting agent based on cas9 protein from demequina sediminicola bacteria |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| CA3169272A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| US20230232796A1 (en) | 2020-06-26 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| JP2024509194A (en) | 2021-03-05 | 2024-02-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | In vivo DNA assembly and analysis |
| AU2022381205A1 (en) | 2021-11-04 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| US20230257432A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
| WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
| WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| WO1998041645A1 (en) | 1997-03-14 | 1998-09-24 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| EP1141360A4 (en) | 1998-12-31 | 2002-11-06 | David Gladstone Inst | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| JP2002535995A (en) | 1999-02-03 | 2002-10-29 | ザ チルドレンズ メディカル センター コーポレイション | Gene repair involving induction of double-stranded DNA breaks at chromosomal target sites |
| ATE309536T1 (en) * | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | METHODS OF USING RANDOMIZED ZINC FINGER PROTEIN LIBRARIES TO IDENTIFY GENE FUNCTIONS |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) * | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| CN100575485C (en) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | Use the directed karyomit(e) mutagenesis of Zinc finger nuclease |
| CA2479858A1 (en) | 2002-03-21 | 2003-10-02 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| JP2006517101A (en) * | 2003-01-13 | 2006-07-20 | エス． ラオ、マヘンドラ | Sustained expression of candidate molecules in proliferating stem and progenitor cells to deliver therapeutic products |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP2927318B1 (en) | 2003-08-08 | 2020-05-20 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2006033859A2 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| DK1802193T3 (en) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Method of producing a homozygous mouse for genetic modification |
| FR2879622B1 (en) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | IN VITRO PROCESS FOR THE PRODUCTION OF OOCYTES OR EGGS WITH TARGETED GENOMIC MODIFICATION |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| ATE489465T1 (en) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | TARGETED INTEGRATION INTO THE PPP1R12C POSITION |
| PT2602323T (en) | 2007-06-01 | 2018-04-02 | Open Monoclonal Tech Inc | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| JP5908725B2 (en) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Methods and compositions for targeted single-strand cleavage and targeted integration |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
| EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| US8722964B2 (en) | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| US8558055B2 (en) | 2009-07-24 | 2013-10-15 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease |
| CA2779337A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) | Homologous recombination in the oocyte |
| PL2494047T3 (en) | 2009-10-29 | 2017-05-31 | Regeneron Pharmaceuticals, Inc. | Multifunctional alleles |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| EP2508595B1 (en) | 2009-12-01 | 2016-11-23 | National Cancer Center | Method for constructing chimeric rat using rat embryonic stem cells |
| PL2816112T3 (en) | 2009-12-10 | 2019-03-29 | Regents Of The University Of Minnesota | Tal effector-mediated DNA modification |
| EP2516652B1 (en) | 2009-12-21 | 2014-11-05 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| CN102843904B (en) | 2010-01-22 | 2015-01-21 | 陶氏益农公司 | Excision of transgenes in genetically modified organisms |
| WO2011100058A1 (en) * | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| EP2579711B1 (en) | 2010-06-11 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
| US8945868B2 (en) * | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
| WO2012018726A1 (en) | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| WO2012168307A2 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| IL305550A (en) | 2011-10-28 | 2023-10-01 | Regeneron Pharma | Genetically modified t cell receptor mice |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| SG10201702445TA (en) | 2012-04-25 | 2017-04-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| CA2871524C (en) | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| RS64622B1 (en) | 2012-05-25 | 2023-10-31 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| MX2014015204A (en) | 2012-06-12 | 2015-08-07 | Genentech Inc | Methods and compositions for generating conditional knock-out alleles. |
| ES2757623T3 (en) | 2012-07-25 | 2020-04-29 | Broad Inst Inc | Inducible DNA binding proteins and genomic disruption tools and applications thereof |
| JP6517143B2 (en) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | Composition for cleaving target DNA comprising guide RNA specific for target DNA and CAS protein encoding nucleic acid or CAS protein, and use thereof |
| KR102006880B1 (en) | 2012-12-06 | 2019-08-02 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-based genome modification and regulation |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| PT2896697E (en) | 2012-12-12 | 2015-12-31 | Massachusetts Inst Technology | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093718A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| PT2898075E (en) | 2012-12-12 | 2016-06-16 | Harvard College | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| EP4286402A3 (en) | 2012-12-12 | 2024-02-14 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| SG11201504621RA (en) | 2012-12-17 | 2015-07-30 | Harvard College | Rna-guided human genome engineering |
| FI3491915T3 (en) | 2012-12-27 | 2023-08-29 | Keygene Nv | Method for inducing a targeted translocation in a plant. |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| ES2904803T3 (en) | 2013-02-20 | 2022-04-06 | Regeneron Pharma | Genetic modification of rats |
| AU2014218621B2 (en) | 2013-02-25 | 2019-11-07 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| WO2014131833A1 (en) | 2013-02-27 | 2014-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gene editing in the oocyte by cas9 nucleases |
| US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
| ES2901396T3 (en) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Nucleic Acid Targeting Nucleic Acid Compositions and Methods |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| JP2016522679A (en) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing with the CRISPR / Cas system |
| RS58255B1 (en) * | 2013-04-16 | 2019-03-29 | Regeneron Pharma | Targeted modification of rat genome |
| US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| WO2014172470A2 (en) | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
| EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
| US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
| WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| RU2704283C9 (en) | 2014-06-06 | 2020-02-07 | Регенерон Фармасьютикалз, Инк. | Methods and compositions for modifying target locus |
| ES2694629T3 (en) | 2014-06-26 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for objective genetic modifications and methods of use |
| CA2954414A1 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| KR102530821B1 (en) | 2014-12-19 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | Methods and compositions for targeted genetic modification through single-step multiple targeting |
-
2013
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 MX MX2014012994A patent/MX362523B/en active IP Right Grant
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en active Application Filing
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/en active
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/en active Active
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/en active IP Right Grant
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/en active Active
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/en active Active
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/en active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/en unknown
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/en active Active
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 PT PT137207189T patent/PT2847335T/en unknown
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2015
- 2015-08-24 HK HK15108155.7A patent/HK1207396A1/en unknown
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1120572T1 (en) | 2019-07-10 |
| US20130309670A1 (en) | 2013-11-21 |
| KR20150004816A (en) | 2015-01-13 |
| US10301646B2 (en) | 2019-05-28 |
| AU2013251558B2 (en) | 2019-01-03 |
| ES2683071T3 (en) | 2018-09-24 |
| CA2869016A1 (en) | 2013-10-31 |
| SG10201702445TA (en) | 2017-04-27 |
| MX362523B (en) | 2019-01-22 |
| CN104364380B (en) | 2018-10-09 |
| PL2847335T3 (en) | 2019-01-31 |
| HK1207396A1 (en) | 2016-01-29 |
| PT2847335T (en) | 2018-09-28 |
| EP2847335A1 (en) | 2015-03-18 |
| AU2013251558A1 (en) | 2014-10-02 |
| WO2013163394A1 (en) | 2013-10-31 |
| EP2847335B1 (en) | 2018-06-27 |
| US20180037910A1 (en) | 2018-02-08 |
| IL234905B (en) | 2018-10-31 |
| DK2847335T3 (en) | 2018-08-13 |
| CN104364380A (en) | 2015-02-18 |
| CN109536526A (en) | 2019-03-29 |
| US9834786B2 (en) | 2017-12-05 |
| JP6275120B2 (en) | 2018-02-07 |
| MX2014012994A (en) | 2015-02-04 |
| CA2869016C (en) | 2020-05-05 |
| KR101904508B1 (en) | 2018-10-04 |
| CN109536526B (en) | 2020-06-09 |
| IN2014DN09261A (en) | 2015-07-10 |
| JP2015514439A (en) | 2015-05-21 |
| BR112014026294A2 (en) | 2020-07-07 |
| RU2014145942A (en) | 2016-06-10 |
| RU2645475C2 (en) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207396A1 (en) | Nuclease-mediated targeting with large targeting vectors | |
| IL236563A (en) | Search-powered connection targeting | |
| GB201217807D0 (en) | Location-assisted beamforming | |
| EP2940755A4 (en) | Assembled battery | |
| EP2866324A4 (en) | Charger | |
| AU347859S (en) | Battery | |
| AU346864S (en) | Battery | |
| PL2713471T3 (en) | Charger | |
| HK1180931A1 (en) | An electro-pulsograph | |
| ZA201500911B (en) | Enzymes | |
| EP2887796A4 (en) | Multiple-virus-resistant melon | |
| EP2874517A4 (en) | Seat-lift assembly | |
| GB2506566B (en) | Pole piece | |
| GB201212340D0 (en) | Antennas | |
| GB201420527D0 (en) | Electrical-wire-protecting member | |
| EP2916451A4 (en) | Electricity-generating system | |
| EP2812436A4 (en) | Mini-intronic plasmid vectors | |
| EP2865582A4 (en) | Frp member | |
| EP2899772A4 (en) | Battery assembly | |
| GB201214720D0 (en) | Maser assembly | |
| EP2874204A4 (en) | Battery assembly | |
| EP2905847A4 (en) | Assembly | |
| EP2824757A4 (en) | Assembled battery | |
| GB201206455D0 (en) | Gene expression | |
| GB2518076B (en) | Electrical-wire-protecting member |